Vital Signs

This issue of Vital Signs, released on February 21, 2011, provides a strategic insight on how cancer diagnostic companies can reach out to their customer base. Additionally, a company spotlight is provided for BioMarker Strategies, a novel tissue-based cancer diagnostics company that is developing the SnapPathTM ex vivo biomarker platform to improv...

This issue of Vital Signs, released on February 14, 2011, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharmaceuticals and Biotechnology, Medical Devices, In Vitro Diagnostics and Life Science Research Tools.

This issue of Vital Signs, released on February 7, 2011, provides a strategic overview of influences of cloud computing in the medical imaging market. Additionally, a company spotlight is provided for Biotronics3D, a novel company that distributes medical imaging services with advanced visualization productivity and analysis tools without the need ...

This issue of Vital Signs, released on January 26, 2011, provides a strategic overview of the next generation of medical implant technologies. Additionally, a company spotlight is provided for Ardian, Inc., a novel catheter-based treatment company for diseases related to sympathetic hyperactivity, including hypertension, chronic kidney disease, ins...

This issue of Vital Signs, released on January 17, 2011, provides a strategic overview of CETP inhibitor treatments in development for dyslipidemia. Additionally, a company spotlight is provided for DARA BioSciences, a development stage biopharmaceutical company. Reimbursement and regulatory news from the FDA is also provided for the week of Decemb...

This issue of Vital Signs, released on December 20, 2010, provides a strategic overview of the integration and changes to the cardiopulmonary resuscitation sequence. Additionally, a company spotlight is provided for Echo Therapeutics, a transdermal medical device company with deep expertise in advanced skin permeation technology. Reimbursement and ...

This issue of Vital Signs, released on December 6, 2010, provides a strategic overview of key issues and trends relating to next-generation sequencing. Additionally, a company spotlight is provided for GenturaDx, a company who has an exclusive license to more than 100 patents for assays, which should allow the company to develop an incredibly broad...

This issue of Vital Signs, released on November 15, 2010, provides a strategic overview of key issues and trends relating to the lack of standardized acute care world wide. Additionally, a company spotlight is provided for Insera Therapeutics, LLC, an innovative medical device developer addressing solutions for complex neurovascular diseases. Reimb...

This issue of Vital Signs, released on November 8, 2010, provides a strategic overview of key issues and trends relating to prescription medications for long-term weight loss. Additionally, a company spotlight is provided for Vitae Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on building a portfolio of novel, small mole...